Sepsis-induced expansion of granulocytic myeloid-derived suppressor cells promotes tumour growth through Toll-like receptor 4

Journal of Pathology

Volumn 239, Issue 4, 2016, Pages 473-483

  Llitjos, Jean François ^a,b,c   Auffray, Cédric ^a,b   Alby Laurent, Fanny ^a,b   Rousseau, Christophe ^a,b   Merdji, Hamid ^a,b   Bonilla, Nelly ^a,b   Toubiana, Julie ^a,b   Belaïdouni, Nadia ^a,b   Mira, Jean Paul ^a,b,c   Lucas, Bruno ^a,b   Chiche, Jean Daniel ^a,b,c   Pène, Frédéric ^a,b,c  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Institut Cochin   (France)

Author keywords

cancer; mouse; myeloid derived suppressor cell; sepsis; Toll like receptor

Indexed keywords

CD11B ANTIGEN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL PERITONITIS; BONE MARROW CELL; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVOR; CELL EXPANSION; CONTROLLED STUDY; DISEASE SEVERITY; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; SEPSIS; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84979201260     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4744     Document Type: Article

References (47)

1. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013; 13: 862–874.
2. Daviaud F, Grimaldi D, Dechartres A, et al. Timing and causes of death in septic shock. Ann Intens Care 2015; 5: 58.
3. Benjamim CF, Lundy SK, Lukacs NW, et al. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 2005; 105: 3588–3595.
4. Pène F, Zuber B, Courtine E, et al. Dendritic cells modulate lung response to Pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol 2008; 181: 8513–8520.
5. Wunsch H, Guerra C, Barnato AE, et al. Three-year outcomes for Medicare beneficiaries who survive intensive care. J Am Med Assoc 2010; 303: 849–856.
6. Quartin AA, Schein RM, Kett DH, et al. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. J Am Med Assoc 1997; 277: 1058–1063.
7. Yende S, D'Angelo G, Kellum JA, et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008; 177: 1242–1247.
8. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6: 715–727.
9. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med 2014; 371: 380–383.
10. + regulatory T cells. J Immunol 2008; 180: 1565–1575.
11. Shu SY, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas. Cancer Res 1985; 45: 1657–1662.
12. International Cell Line Authentification Committee [Internet]; http://iclac.org/wp-content/uploads/Cross-Contaminations-v7_2.pdf [accessed 20 November 2015].
13. National Center for Biotechnology Information, BioSample database; http://www.ncbi.nlm.nih.gov/biosample/?term=cell%20line%20status%20misidentified[Attribute] [accessed 20 November 2015].
14. + T cells. Proc Natl Acad Sci USA 2013; 110: 13085–13090.
15. Luo Y, Dorf ME. Isolation of mouse neutrophils. Curr Protoc Immunol 2001; 3: Unit 3.20.
16. Corraliza IM, Campo ML, Soler G, et al. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994; 174: 231–235.
17. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer – analyses of cohorts of twins from Sweden, Denmark and Finland. N Engl J Med 2000; 343: 78–85.
18. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607–615.
19. Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29: 2897–2903.
20. Lindqvist EK, Goldin LR, Landgren O, et al. Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 2011; 118: 6284–6291.
21. Cavassani KA, Carson WF 4th, Moreira AP, et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010; 115: 4403–4411.
22. Kumagai K, Saikawa Y, Takeuchi H, et al. The neutrophil elastase inhibitor sivelestat suppresses accelerated gastrointestinal tumor growth via peritonitis after cecal ligation and puncture. Anticancer Res 2013; 33: 3653–3659.
23. Pidgeon GP, Harmey JH, Kay E, et al. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999; 81: 1311–1317.
24. Chen L, He Z, Qin L, et al. Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One 2011; 6: e24407.
25. Sfondrini L, Rossini A, Besusso D, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006; 176: 6624–6630.
26. + T-cell activation events. Eur J Immunol 2013; 43: 2930–2942.
27. Monu NR, Frey AB. Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship. Immunol Invest 2012; 41: 595–613.
28. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53–65.
29. Brudecki L, Ferguson DA, McCall CE, et al. Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response. Infect Immun 2012; 80: 2026–2034.
30. + population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007; 204: 1463–1474.
31. Derive M, Bouazza Y, Alauzet C, et al. Myeloid-derived suppressor cells control microbial sepsis. Intens Care Med 2012; 38: 1040–1049.
32. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al. A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 2011; 17: 281–292.
33. Guerin E, Orabona M, Raquil MA, et al. Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration. Crit Care Med 2014; 42: 2007–2018.
34. Gey A, Tadie JM, Caumont-Prim A, et al. Granulocytic myeloid-derived suppressor cells inversely correlate with plasma arginine and overall survival in critically ill patients. Clin Exp Immunol 2015; 180: 280–288.
35. Pène F, Courtine E, Ouaaz F, et al. Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells. Infect Immun 2009; 77: 5651–5658.
36. Plitas G, Burt BM, Nguyen HM, et al. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med 2008; 205: 1277–1283.
37. Peck-Palmer OM, Unsinger J, Chang KC, et al. Deletion of MyD88 markedly attenuates sepsis-induced T and B lymphocyte apoptosis but worsens survival. J Leukoc Biol 2008; 83: 1009–1018.
38. Pène F, Grimaldi D, Zuber B, et al. Toll-like receptor 2 deficiency increases resistance to Pseudomonas aeruginosa pneumonia in the setting of sepsis-induced immune dysfunction. J Infect Dis 2012; 206: 932–942.
39. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009; 9: 57–63.
40. Bohnhorst J, Rasmussen T, Moen SH, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia 2006; 20: 1138–1144.
41. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007; 67: 4346–4352.
42. Bunt SK, Clements VK, Hanson EM, et al. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 2009; 85: 996–1004.
43. + cells to induce apoptosis of activated T cells. J Immunol 2010; 185: 2773–2782.
44. Standiford TJ, Kuick R, Bhan U, et al. TGFβ-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth. Oncogene 2011; 30: 2475–2484.
45. Yang HZ, Cui B, Liu HZ, et al. Blocking TLR2 activity attenuates pulmonary metastases of tumor. PLoS One 2009; 4: e6520.
46. Rutkowski MR, Stephen TL, Svoronos N, et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 2015; 27: 27–40.
47. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050–1059.